SEARCH

SEARCH BY CITATION

References

  • 1
    Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 3414.
  • 2
    Suzuki K, Mizokami M, Cao K, et al. Prevalence of hepatitis C virus infection in Nanjing, southern China. Eur J Epidemiol 1997; 13: 5115.
  • 3
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 55662.
  • 4
    Wu CH, Lee MF, Kuo HS. Distribution of hepatitis C virus genotypes among blood donors in Taiwan. J Gastroenterol Hepatol 1997; 12: 6258.
  • 5
    Sheu JC, Wang JT, Wang TH, et al. Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993; 17: 1928.
  • 6
    Lin HH, Kao JH, Huang SC, Lee TY, Chen PJ, Chen DS. Prevalence, genotypes and antibody titer of hepatitis C virus in pregnant women in Taiwan. J Obstet Gynaecol 1995; 21: 55762.
  • 7
    Chuang WL, Yu ML, Dai CY, Chang WY. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006; 49: 99106.
  • 8
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 9
    Saracco G, Olivero A, Ciancio A, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 2002; 36: 95966.
  • 10
    Malone DC, Tran TT, Poordad FF. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J Manag Care Pharm 2005; 11: 68794.
  • 11
    Grieve R, Roberts J, Wright M, et al. Cost-effectiveness of interferon alfa or peginterferon alfa with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55: 13328.
  • 12
    Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alfa-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8: iiiiv, 1–125.
  • 13
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 14
    Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37: 5909.
  • 15
    Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon alfa-2b plus ribavirin and interferon alfa-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12: 28391.
  • 16
    Lai MY. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan. Intervirology 2006; 49: 915.
  • 17
    Yu ML, Dai CY, Lin ZY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alfa-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006; 26: 7381.
  • 18
    Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002; 65: 11011.
  • 19
    Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 42532.
  • 20
    Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 9939.
  • 21
    Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 68794.
  • 22
    Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97103.
  • 23
    Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 260917.
  • 24
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 226571.
  • 25
    Bruno S, Camma C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 47481.
  • 26
    Berg T, Von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 108697.
  • 27
    Ikeda K, Kumada H, Saitoh S, et al. A randomized controlled trial of interferon-alfa in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus. J Hepatol 1998; 28: 9101.
  • 28
    Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 837.
  • 29
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 148592.
  • 30
    Benckert C, Jonas S, Thelen A, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: prognostic parameters. Transplant Proc 2005; 37: 16934.
  • 31
    McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alfa-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 1407.
  • 32
    Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alfa-2a plus ribavirin versus interferon alfa-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22: 25765.
  • 33
    McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology 2002; 36: S24552.
  • 34
    Hadziyannis SJ. Why and how to treat chronic hepatitis C. Can J Gastroenterol 2000; 14 (Suppl. B): 45B48B.
  • 35
    Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alfa-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000; 95: 152430.
  • 36
    Koff RS. Cost-effectiveness of treatment for chronic hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 2558.
  • 37
    Patel K, McHutchison J. Peginterferon alfa-2b: a new approach to improving response in hepatitis C patients. Expert Opin Pharmacother 2001; 2: 130715.
  • 38
    De Filippi F, Colombo M. Treatment of chronic hepatitis C. J Biol Regul Homeost Agents 2003; 17: 1337.
  • 39
    Colombo M, Rumi MG, Ninno ED. Treatment of chronic hepatitis C in Europe. J Hepatobiliary Pancreat Surg 2003; 10: 16871.
  • 40
    Ishida H, Inoue Y, Wong JB, Okita K. Cost-effectiveness of ribavirin plus interferon alfa-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial. Hepatol Res 2004; 28: 12536.
  • 41
    Arguedas M. Cost effectiveness of peginterferon alfa-2a plus ribavirin versus interferon alfa-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22: 4778, author reply 78–9.
  • 42
    Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med 2000; 108: 36673.
  • 43
    Sinha M, Das A. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000; 19: 2330.
  • 44
    Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alfa 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 131824.